Dr. Okun 429 Report post Posted August 7, 2009 This researcher from NYU has been working on a new potential drug target for the treatment of Dyskinesia Sci Signal. 2009 Jul 21;2(80):pe42. Links Thwarting dyskinesia by targeting mTORC1. Klann E. Center for Neural Science, New York University, New York, NY 10003, USA. eklann@cns.nyu.edu In a mouse model of Parkinson's disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by l-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by l-DOPA treatment in patients with Parkinson's disease. Share this post Link to post Share on other sites
Guest Report post Posted November 9, 2009 Seriously interesting. Share this post Link to post Share on other sites
Dr. Okun 429 Report post Posted November 11, 2009 Thanks for the comment. Share this post Link to post Share on other sites
